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Optimal Therapy for 
Multidrug-Resistant 
Acinetobacter 
baumannii
To the Editor: I read with inter-
est the article by Doi et al. about a lung 
transplant patient presumed to have 
Acinetobacter baumannii ventilator-
associated pneumonia (1), but some 
points deserve comment. A. baumannii 
is a relatively avirulent organism that 
frequently colonizes body ﬂ  uids. For 
multidrug-resistant strains, antimicrobi-
al drug selection is limited. Resolution 
of this patient’s pulmonary inﬁ  ltrates 
suggests that they were not caused by 
A. baumannii that persisted in respira-
tory secretions. Because A. baumannii 
persisted in this patient’s respiratory 
secretions, colistin and cefepime were 
given. Colistin is an antimicrobial drug 
with low resistance potential; but when 
given by inhalation, it may lead to drug 
resistance (2,3). 
Doi et al. stated that the patient’s 
A. baumannii strain lacked susceptibil-
ity to all available antimicrobial drugs 
but that cefepime and tigecycline were 
intermediately susceptible (MICs 16 
μg/mL and 2.0 μg/mL, respectively) 
(1). Intermediate susceptibility may 
also be interpreted as relatively sus-
ceptible when achievable serum or 
tissue concentrations exceed the MIC. 
The article did not mention the dosages 
of colistin, tigecycline, and cefepime. 
A 2-g dose of cefepime given intrave-
nously results in peak serum levels of 
≈163 μg/mL with a relatively low vol-
ume of distribution (0.29 L/kg), which 
would not be expected to eradicate A. 
baumannii in respiratory secretions. 
High-dose intravenous tigecycline 
(initial dose of 200 mg followed by 
100 mg daily) has been used to treat A. 
baumannii, achieving peak concentra-
tions of ≈3 μg/mL, which exceed the 
isolate’s MIC of 2 μg/mL, and a high 
volume of distribution (8 L/kg), which 
would be expected to eradicate A. bau-
manii in respiratory secretions.
Optimal treatment for A. bauman-
nii depends on susceptibility, phar-
macokinetic principles, and site of 
infection. For optimal effectiveness, 
cefepime and tigecycline should have 
been given at high doses. To prevent 
potential resistance, antimicrobial 
drugs should not be given by inhala-
tion (3). The alleged advantage of 
inhalation therapy is high local drug 
concentrations, but concentrations in 
some alveoli may be subtherapeutic 
(3). If possible, tigecycline should not 
be used to treat A. baumannii infec-
tions; however, if it is used, high doses 
should be given to optimize its phar-
macokinetic attributes (4,5).
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In Response:  We welcome Burke 
A. Cunha’s letter (1) but disagree with 
him regarding 4 issues. First, he states 
that colistin has a “low resistance po-
tential” (1). Although colistin has had 
low resistance for a long time, we are 
concerned that development of resis-
tance to colistin is a growing problem. 
Heteroresistant Acinetobacter isolates 
are readily found (2). Lee et al. (3) re-
cently found decreases in polymyxin 
B susceptibility during therapy.
Second, Cunha states, “Interme-
diate susceptibility may also be inter-
preted as relatively susceptible when 
achievable serum or tissue concentra-
tions exceed the MIC” (1). We sup-
port the concepts that break points are 
artiﬁ   cial and that pharmacodynamic 
optimization may enable treatment 
for some organisms that are not sus-
ceptible to certain antimicrobial drugs. 
However, consideration of more than 
the MIC is necessary. Cefepime is 
a time-dependent bactericidal drug; 
therefore, effectiveness depends more 
on the time that the concentration of 
drug is above the MIC than on peak 
serum concentrations.
Third, Cunha states, “For optimal 
effectiveness, cefepime and tigecycline 
should have been given at high doses” 
(1). Unfortunately, in the current era 
of antimicrobial drug resistance, there 
are no “shoulds.” The high-dose tige-
cycline regimen that Cunha proposes 
for multidrug-resistant organisms has 
never, to our knowledge, been evalu-
ated in randomized trials or even in 
large prospective evaluations. We all 
must admit that we do not know the 
optimal way to treat such infections 
and that we need rigorous evaluation 
of novel regimens. Anecdotal experi-
ence must not be translated into im-
peratives.
Fourth, Cunha states that “antimi-
crobial drugs should not be given by 
inhalation” (1). We agree that wide-
spread use of aerosolized antimicro-
bial drugs cannot be recommended. 
However, aerosolized amikacin with 
a new-generation nebulizer is being 
tested in phase 2 clinical trials (4). As 
to the potential utility of aerosolized 
antimicrobial drugs, we prefer to keep 
an open mind pending the results of 
these trials.
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